Start here · since 1996

Psychedelics Guide

More than 500 articles organized by substance and topic: psilocybin, LSD, ayahuasca, DMT, MDMA, mescaline and harm reduction. Rigorous information, without fear and without propaganda.

Featured articles

Explore the largest archive on psychoactive substances, published since 1996

US Psychedelic Helpline: Insights from 25,419 Interactions

A Science Advances paper details 25,419 contacts with the Fireside Project (2021-2026), primarily regarding psilocybin and trip support. Among interactions with recorded history, 2.4% mentioned schizophrenia. The data reflects only those who reached out.

Persistent difficulties after psychedelics or meditation: Emory publishes a protocol for a 1,600-person study

A team led by Emory University has posted on medRxiv the protocol for an observational study that will follow, for one year, people who attribute persistent difficulties to psychedelics or meditation. It is a research plan with no data. The sample is deliberately recruited among affected people, so it is not designed to estimate how often these problems occur.

Mind & Spirit

Inspiring reads for open minds

From our readers

Articles chosen by our community of readers

Send us your story and get featured on our homepage

Amphetamines: History, Pharmacology, and Risks of a Stimulant

Synthetic derivatives of ephedrine, these drugs appeared in US pharmacies around 1930 as a way to keep patients awake after sedative overdoses. Shortly after, they were launched as inhalers for colds and nasal congestion, later as pills for motion sickness and obesity, and finally as antidepressants. Following amphetamine itself (Benzedrine, Sympatina, Profamina, Centramina, etc.), its isomer dexamphetamine (Dexedrine) appeared, and in 1938, methamphetamine (Methedrine).

Cannabis and Meditation: Examining the Content-Free Mind

Can meditation and cannabis lead to a thought-free mind? A sober examination of the content-free state, its limits, and its risks.

Recreational vs. Clinical Ketamine: Uses and Harm Reduction

What separates supervised clinical ketamine from recreational use: mechanisms, EMA and FDA-approved indications, bladder and kidney risks, and harm reduction.

The Evolution of Drug Advertising: From Prohibition to Responsibility

The landscape of psychoactive substance advertising has undergone a radical transformation. Once-imposing, radical discourses now coexist with strategies adapted to the social environment. This article explores how "responsible use" has become the dominant paradigm.

Harm Reduction: Between Scientific Evidence and Political Rhetoric

A critical analysis of how public health harm reduction strategies face sensationalist headlines, statistical ignorance, and polarization.

News

The latest from the psychedelic world

Latest articles

Browse our most recent articles